prophylactic thiamine to reduce neurologic aes in patients with mf treated with fedratinib
Published 3 months ago • 44 plays • Length 0:51Download video MP4
Download video MP3
Similar videos
-
1:16
using rwd to evaluate the use of fedratinib as a potential bridge to hsct in patients with mf
-
1:17
the use of pacritinib in thrombocytopenic patients with myelofibrosis undergoing allosct
-
2:12
refine: phase ii study of navitoclax ruxolitinib in jak inhibitor-naive patients with mf
-
5:27
uvea-ixa: exploring the use of ixazomib-based therapy in r/r myeloma outside of clinical trials
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
4:48
an insight into the management of cytopenias in mf
-
1:35
pirtobrutinib in r/r fl: results from the bruin study
-
3:02
the recent withdrawal of voxelotor from the market: the potential impact on patients with scd
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
1:20
the impact of early ruxolitinib treatment on os in the comfort-i and comfort-ii studies
-
1:29
insights into the uses of ibrutinib for patients with waldenström’s macroglobulinemia
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
5:00
long-term results of the phase ii revive study evaluating rusfertide in patients with pv
-
1:35
phase i/ii bruin update: efficacy of pirtobrutinib in r/r waldenström's macroglobulinemia
-
3:56
results of the phase ii titan study of caplacizumab in patients with attp
-
25:40
vitamin b1 (thiamine) deficiency: cardiovascular & circulatory diseases
-
0:49
the importance of basic science research in hemoglobinopathies
-
1:02
a phase ii single-arm study of obinutuzumab plus ibrutinib as frontline treatment for fl and mzl
-
3:42
vitamin b1 (thiamine)